



AURORA

E C O N O M I C
D E V E L O P M E N T
C O U N C I L



Aurora Bioscience Industry

Colorado has approximately 17,150 private-sector bioscience workers in nearly 650 companies made-up primarily of medical device and instrument, as well as pharmaceutical and biotechnology firms. Colorado ranks seventh in the nation for its 2009 concentration of medical device and instrument employment (11,080 jobs). The 2008 average salary for a worker in this sub-category was \$63,080 (\$69,100 nationwide). Colorado ranks 21st in the nation for its 2009 concentration of pharmaceutical and biotechnology employment (6,070 jobs). The 2008 average salary for a worker in this sub-category was \$88,820 (\$95,760 nationwide).

Aurora is home to the Anschutz Medical Campus and Fitzsimons Life Science District located at I-225 and Colfax Avenue in Aurora. The site, which currently employs more than 16,000, is the home of the University of Colorado Denver health sciences operations, the University of Colorado Hospital, The Children's Hospital, the new Veterans Administration Hospital, and several other centers for health care, biomedical research and workforce development. This project contributed \$3.5 billion dollars to the state's economy in 2008 with \$1.4 billion generated in personal income. By 2013, the site will employ 21,041 directly, contribute \$4.5 billion annually to Colorado's economy and generate \$1.8 billion in personal income. At build-out, the Anschutz/Fitzsimons site will be a \$5.2 billion investment, consist of approximately 18.5 million square feet and employ 44,569 people. The University of Colorado Hospital is undergoing a \$400 million expansion, the largest addition to the hospital since it moved to the campus in 2007. The expansion includes a new, 660,000 square-foot, 12-story tower, a \$67 million electronic record conversion and a \$20 million cancer center expansion - creating 1,400 jobs. The Children's Hospital recently broke ground on a \$230 million, new patient tower at its main campus at the Anschutz Medical Campus in Aurora. Construction of the new 10-story, 350,000 square-foot facility has an anticipated operational date of late 2012 and will create 500 new jobs.

To the south of Anschutz/Fitzsimons is a city designated Urban Renewal District known as the Fitzsimons Boundary Area. It consists of 110-acres along East Colfax Avenue from Potomac Street to Peoria Street. The city urban renewal plan for the district supports redevelopment, planning and zoning changes, land use changes, maximum densities and building requirements that will complement the Anschutz/Fitzsimons development. The city of Aurora uses several techniques to fund redevelopment including tax increment financing, general funds from the city, and by private sector investment to help create jobs and bolster the economy in what was once an economically depressed area. This area is also a designated state enterprise zone. Corporex broke ground in May 2010 on Fitzsimons Village, a 32-acre mixed-use development consisting of class A office/medical buildings, hotels and retail amenities to the Anschutz Medical Campus and Fitzsimons Life Science District. Fitzsimons Village connects to the Medical Campus via an elevated pedestrian walkway.

Due to the coordination and efforts to secure funding by the Colorado Congressional delegation, Accelerate Colorado, the Aurora Economic Development Council and the Anschutz/Fitzsimons Stakeholders Group, a new interchange will be constructed at I-225 and Colfax Avenue/17th Place to service the more than 23,000 visitors to Anschutz/Fitzsimons every day. This partnership is also working on the widening of I-225 and obtaining federal funding to bring FasTracks to the site. Once funding is secured, the I-225 FasTracks light rail line will have two stations to service Anschutz/Fitzsimons – one just west of I-225 on Colfax Avenue and the other on Montview Boulevard in the center of the campus.

Technology transfer is another contributor to the private-sector of the bioscience industry. The University of Colorado Technology Transfer Office is ranked among the top 20 universities for creating startup companies by the Association of University Technology Managers. Of the 160 U.S. universities, CU tied for tenth place for the number of startup companies created in fiscal year 2008. In the past five years, 51 companies have been formed based on CU intellectual property – of these 51 companies, 44 are operational as either stand alone or subsidiary/merged companies – 42 having operations in Colorado.

The Colorado Institute for Drug, Device, and Diagnostic Development (CID4), located on the Fitzsimons Life Science District, is a private not-for-profit entity which provides management expertise and funding to efficiently transform emerging life science technologies into commercial successes. CID4 does this by identifying and actively managing promising life science technology investments. CID4's mission is to accelerate the commercialization of life science discoveries made within the state's research institutions and private start-up companies; insure greater success in creating and retaining Colorado life science companies; and to create the desirable jobs associated with the life sciences industry. Over the first five years of operation, 12 new technologies will be steered through the early stages of development by CID4 resulting in new local companies, financeable by the private sector. CID4 will help Colorado better develop and protect a dynamic bioscience industry by accelerating the formation and growth of promising life science technologies.

In 2009, Colorado received a total of \$437 million in funding from the National Institutes for Health (NIH). That includes \$375 million from regular appropriations and an additional \$62 million from the American Recovery and Reinvestment Act funding. The University of Colorado Denver's Anschutz Medical Campus received 525 sponsored research awards in 2009 for \$165,400,485. This amounts to 45% of the campus's sponsored research awards, making NIH its highest grant funding agency. For every \$1 million invested in NIH, more than 30 jobs are created/sustained, and research in areas involving cancer, neurological diseases, diabetes, diseases in children, and other important diseases is furthered.